TNFRSF8/CD30 (C-Term) Rabbit Monoclonal Antibody (Clone RM425)

CD30, also known as tumor necrosis factor receptor superfamily member 8 (TNFRSF8), is a type I transmembrane glycoprotein encoded by TNFRSF8 in humans.^1,2 Alternative splicing of the TNFRSF8 pre-mRNA produces one full-length isoform, CD30 long, and two short isoforms that contain truncated transmembrane and/or extracellular domains.^1,3 CD30 exists as a monomer and is composed of an extracellular domain containing three cysteine-rich repeats (CRDs), a transmembrane domain, and a C-terminal cytoplasmic domain that facilitates intracellular signaling.² It is expressed on certain subsets of activated T- or B cells, as well as in a variety of lymphoid neoplasms, including Hodgkin lymphoma and anaplastic large cell lymphomas (ALCLs).¹ It can also exist in a soluble form, which is produced by proteolytic cleavage of CD30 at the cell surface and is found in the serum.^1,2 CD30 is upregulated by mitogens, such as phorbol 12-myristate 13-acetate (TPA; Item No. 10008014), or viral stimulation, including Epstein-Barr virus (EBV) or HIV, as well as by the transcription factor JunB.^1,3 Upon interaction with its ligand, TNFSF8/CD30L, which is also expressed on certain subsets of activated lymphocytes, CD30 assembles into a trimer that recruits TNF receptor-associated factor 1 (TRAF1), TRAF2, and TRAF5 to induce NF-κB- or ERK/MAPK-dependent downstream signaling, mediating a variety of cellular processes, including NF-κB activation, cell proliferation and survival, as well as apoptosis.^1,2 Neutralization of CD30 with a monoclonal antibody reduces tumor growth in an ALCL patient-derived xenograft (PDX) mouse model.⁴ Serum levels of soluble CD30 (sCD30) are correlated with disease stage in patients with Hodgkin lymphoma or systemic lupus erythematosus (SLE).² Cayman’s TNFRSF8/CD30 (C-Term) Rabbit Monoclonal Antibody (Clone RM425) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.

WARNING This product is not for human or veterinary use.

1. Gottesman, S.R.S. CD30: Receptor, marker, target. Pathol. Lab. Med. Int. 8(1), 27-36 (2016).

2. van de Weyden, C.A., Pileri, S.A., Feldman, A.L., et al. Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions. Blood Cancer J. 7(9), e603 (2017).

3. Horie, R., Ito, K., Tatewaki, M., et al. A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 88(7), 2422-2432 (1996).

4. Pfeifer, W., Levi, E., Petrogiannis-Hailotis, T., et al. A murine xenograft model for human CD301+ anaplastic large cell lymphoma. Am. J. Pathol. 155(4), 1353-1359 (1999).